Galectin-3 and outcomes after anterior-wall myocardial infarction treated by primary percutaneous coronary...

Area of Science:

• Cardiology
• Biomarker Research
• Clinical Outcomes

Background:

• Galectin-3 (Gal-3) is a biomarker linked to inflammation, tissue repair, and fibrogenesis.
• Its association with left ventricular remodeling post-STEMI is known, but long-term prognostic value is unclear.

Purpose of the Study:

• To investigate the relationship between early Galectin-3 levels and long-term outcomes in patients with anterior ST-elevated myocardial infarction (STEMI).
• To determine if Gal-3 can serve as an independent predictor of adverse events post-primary angioplasty.

Main Methods:

• A cohort of 103 patients with first anterior STEMI treated with primary angioplasty were enrolled.
• Galectin-3 (Gal-3) and NT-proBNP levels were measured early post-procedure.
• Patients were followed for a median of 18 months for major adverse cardiac events (death or heart failure hospitalization).

Main Results:

• Higher Galectin-3 levels independently predicted adverse long-term outcomes after STEMI, even after adjusting for clinical and echocardiographic factors.
• Event-free survival was significantly lower in patients with Gal-3 levels ≥16.8 ng/ml (42.3%) compared to those with levels <16.8 ng/ml (93.5%).
• The study identified Gal-3 as an independent predictor of the combined endpoint (hazard ratio: 1.11; 95% CI: 1.05-1.17 per 1 ng/ml increase).

Conclusions:

• Early post-angioplasty Galectin-3 levels are valuable for risk stratification in patients with anterior STEMI.
• Gal-3 may help identify patients at higher risk for adverse long-term outcomes, guiding further management strategies.